This clinical trial is focused on studying a condition known as Heart Failure with Reduced Ejection Fraction (HFrEF). This is a type of heart failure where the heart muscle does not contract effectively, and less oxygen-rich blood is pumped out to the body. The study will evaluate a new treatment called JTT-861, which is taken as a capsule. The purpose of the study is to assess how well JTT-861 works, its safety, and how the body processes it over a period of 12 weeks.
Participants in the study will be randomly assigned to receive either the JTT-861 capsule or a placebo tablet. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are not biased. The study will last for 12 weeks, during which participants will take the assigned capsule daily. Throughout the study, participants will have regular check-ups to monitor their heart function and overall health.
The study aims to gather information on how JTT-861 affects heart function, including changes in heart size and pumping ability, as well as levels of certain proteins in the blood that are related to heart failure. Safety will also be closely monitored by checking for any side effects and changes in vital signs. This research is important for understanding whether JTT-861 could be a beneficial treatment option for people with heart failure.
Bulgaria 
Czechia 
Poland 
Romania 
Spain 
